Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Very low

Seizure frequency reduction (3‐month blinded evaluation period) · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 172 participants
Very low

Treatment withdrawal · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 236 participants
Very low

Adverse effects · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 236 participants
Very low

Quality of life · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low